Analysis of Short-term (Operating) Activity Ratios
Quarterly Data
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Abiomed Inc., short-term (operating) activity ratios (quarterly data)
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
| Short-term activity ratio | Description | The company |
|---|---|---|
| Inventory turnover | An activity ratio calculated as cost of goods sold divided by inventory. | Abiomed Inc. inventory turnover ratio improved from Q4 2022 to Q1 2023 but then deteriorated significantly from Q1 2023 to Q2 2023. |
| Receivables turnover | An activity ratio equal to revenue divided by receivables. | Abiomed Inc. receivables turnover ratio improved from Q4 2022 to Q1 2023 but then deteriorated significantly from Q1 2023 to Q2 2023. |
| Payables turnover | An activity ratio calculated as cost of goods sold divided by payables. | Abiomed Inc. payables turnover ratio increased from Q4 2022 to Q1 2023 and from Q1 2023 to Q2 2023. |
| Working capital turnover | An activity ratio calculated as revenue divided by working capital. | Abiomed Inc. working capital turnover ratio deteriorated from Q4 2022 to Q1 2023 but then slightly improved from Q1 2023 to Q2 2023. |
| Short-term activity ratio | Description | The company |
|---|---|---|
| Average inventory processing period | An activity ratio equal to the number of days in the period divided by inventory turnover over the period. | Abiomed Inc. number of days of inventory outstanding improved from Q4 2022 to Q1 2023 but then deteriorated significantly from Q1 2023 to Q2 2023. |
| Average receivable collection period | An activity ratio equal to the number of days in the period divided by receivables turnover. | |
| Operating cycle | Equal to average inventory processing period plus average receivables collection period. | Abiomed Inc. operating cycle improved from Q4 2022 to Q1 2023 but then deteriorated significantly from Q1 2023 to Q2 2023. |
| Average payables payment period | An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. | Abiomed Inc. number of days of payables outstanding decreased from Q4 2022 to Q1 2023 and from Q1 2023 to Q2 2023. |
| Cash conversion cycle | A financial metric that measures the length of time required for a company to convert cash invested in its operations to cash received as a result of its operations; equal to average inventory processing period plus average receivables collection period minus average payables payment period. | Abiomed Inc. cash conversion cycle improved from Q4 2022 to Q1 2023 but then deteriorated significantly from Q1 2023 to Q2 2023. |
Inventory Turnover
Abiomed Inc., inventory turnover calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||||||
| Cost of revenue | 48,880) | 52,626) | 51,457) | 47,627) | 43,886) | 45,188) | 46,078) | 41,110) | 38,736) | 35,983) | 39,369) | 39,996) | 34,867) | 37,073) | 34,848) | 34,023) | 29,846) | 30,850) | 30,098) | 24,994) | 21,627) | 21,862) | 19,261) | 18,987) | 17,309) | 15,070) | ||||||||
| Inventories, net | 102,237) | 95,373) | 93,981) | 90,199) | 85,986) | 83,661) | 81,059) | 82,448) | 83,209) | 89,284) | 90,088) | 91,193) | 90,295) | 87,726) | 80,942) | 71,808) | 63,656) | 55,781) | 50,204) | 46,891) | 40,632) | 36,926) | 34,931) | 32,053) | 31,491) | 29,093) | ||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||||||
| Inventory turnover1 | 1.96 | 2.05 | 2.00 | 2.03 | 2.05 | 2.05 | 2.00 | 1.88 | 1.85 | 1.68 | 1.68 | 1.61 | 1.56 | 1.55 | 1.60 | 1.74 | 1.82 | 1.93 | 1.96 | 1.87 | 2.01 | 2.10 | 2.02 | — | — | — | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Inventory Turnover, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 2.62 | 2.77 | 3.10 | 3.37 | 3.24 | 3.36 | 3.59 | 3.47 | 3.27 | 2.99 | 2.99 | 2.71 | 2.56 | 2.92 | 3.07 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Cigna Group | 28.53 | 30.04 | 26.13 | 30.87 | 32.34 | 34.32 | 31.58 | 37.54 | 36.13 | 36.50 | 32.70 | 37.84 | 36.30 | 38.13 | 36.70 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | 16.48 | 15.15 | 14.05 | 14.46 | 14.64 | 13.60 | 13.52 | 13.49 | 13.48 | 12.57 | 11.88 | 12.43 | 13.03 | 12.68 | 12.06 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Danaher Corp. | 3.90 | 3.65 | 4.03 | 3.80 | 3.71 | 3.87 | 4.16 | 4.06 | 4.28 | 4.34 | 4.28 | 3.79 | 3.26 | 3.09 | 4.87 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 2.21 | 2.25 | 2.27 | 2.36 | 2.62 | 2.82 | 2.98 | 2.90 | 2.84 | 2.64 | 2.49 | 2.18 | 2.22 | 2.30 | 2.30 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 2.00 | 2.09 | 2.20 | 2.26 | 2.38 | 2.47 | 2.43 | 2.24 | 2.20 | 2.10 | 2.23 | 2.34 | 2.35 | 2.37 | 2.44 | 2.35 | 2.39 | 2.42 | 2.53 | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
1 Q2 2023 Calculation
Inventory turnover
= (Cost of revenueQ2 2023
+ Cost of revenueQ1 2023
+ Cost of revenueQ4 2022
+ Cost of revenueQ3 2022)
÷ Inventories, net
= (48,880 + 52,626 + 51,457 + 47,627)
÷ 102,237 = 1.96
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Inventory turnover | An activity ratio calculated as cost of goods sold divided by inventory. | Abiomed Inc. inventory turnover ratio improved from Q4 2022 to Q1 2023 but then deteriorated significantly from Q1 2023 to Q2 2023. |
Receivables Turnover
Abiomed Inc., receivables turnover calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||||||
| Revenue | 265,921) | 277,149) | 269,850) | 261,176) | 248,142) | 252,585) | 241,245) | 231,663) | 209,764) | 164,850) | 206,659) | 221,584) | 204,974) | 207,666) | 207,081) | 200,563) | 181,778) | 180,010) | 174,436) | 154,022) | 132,823) | 132,468) | 124,680) | 114,674) | 102,955) | 102,995) | ||||||||
| Accounts receivable, net | 94,475) | 91,102) | 90,608) | 88,952) | 89,568) | 88,645) | 97,179) | 92,990) | 80,909) | 82,084) | 84,650) | 100,994) | 94,319) | 86,206) | 90,809) | 88,215) | 74,201) | 67,511) | 70,010) | 64,862) | 57,327) | 53,557) | 54,055) | 50,178) | 46,607) | 41,280) | ||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||||||
| Receivables turnover1 | 11.37 | 11.59 | 11.39 | 11.28 | 10.87 | 10.55 | 8.72 | 8.74 | 9.92 | 9.72 | 9.93 | 8.33 | 8.70 | 9.25 | 8.47 | 8.35 | 9.30 | 9.50 | 8.48 | 8.39 | 8.80 | 8.86 | 8.24 | — | — | — | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Receivables Turnover, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 6.52 | 6.89 | 7.02 | 7.03 | 6.33 | 6.20 | 6.64 | 6.61 | 6.58 | 6.13 | 5.40 | 5.70 | 6.12 | 6.06 | 5.88 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | 11.44 | 11.65 | 11.79 | 11.94 | 11.27 | 11.30 | 11.91 | 11.23 | 11.48 | 11.32 | 12.32 | 11.14 | 11.68 | 11.33 | 13.04 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Danaher Corp. | 7.23 | 7.18 | 6.40 | 7.09 | 6.81 | 6.87 | 6.36 | 6.69 | 6.51 | 6.28 | 5.51 | 5.83 | 5.59 | 5.25 | 5.61 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | 18.82 | 16.53 | 18.81 | 19.51 | 18.80 | 16.67 | 20.66 | 18.93 | 18.81 | 17.39 | 19.72 | 18.91 | 18.04 | 16.74 | 18.20 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Humana Inc. | 68.53 | 30.60 | 55.25 | 56.74 | 26.54 | 27.18 | 45.69 | 42.91 | 32.51 | 35.43 | 66.78 | 64.58 | 31.30 | 33.43 | 60.97 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 7.37 | 6.95 | 6.60 | 7.20 | 7.11 | 6.52 | 7.30 | 7.90 | 7.38 | 6.96 | 6.75 | 7.32 | 8.56 | 8.73 | 6.94 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 5.48 | 5.85 | 5.71 | 5.84 | 5.79 | 5.82 | 5.51 | 5.35 | 5.21 | 5.73 | 6.22 | 4.97 | 5.05 | 5.20 | 4.91 | 5.22 | 5.29 | 5.28 | 5.00 | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | 19.23 | 14.88 | 18.22 | 18.37 | 16.27 | 15.65 | 20.07 | 19.60 | 18.53 | 16.35 | 19.86 | 20.63 | 19.62 | 16.73 | 20.32 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
1 Q2 2023 Calculation
Receivables turnover
= (RevenueQ2 2023
+ RevenueQ1 2023
+ RevenueQ4 2022
+ RevenueQ3 2022)
÷ Accounts receivable, net
= (265,921 + 277,149 + 269,850 + 261,176)
÷ 94,475 = 11.37
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Receivables turnover | An activity ratio equal to revenue divided by receivables. | Abiomed Inc. receivables turnover ratio improved from Q4 2022 to Q1 2023 but then deteriorated significantly from Q1 2023 to Q2 2023. |
Payables Turnover
Abiomed Inc., payables turnover calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||||||
| Cost of revenue | 48,880) | 52,626) | 51,457) | 47,627) | 43,886) | 45,188) | 46,078) | 41,110) | 38,736) | 35,983) | 39,369) | 39,996) | 34,867) | 37,073) | 34,848) | 34,023) | 29,846) | 30,850) | 30,098) | 24,994) | 21,627) | 21,862) | 19,261) | 18,987) | 17,309) | 15,070) | ||||||||
| Accounts payable | 35,070) | 34,797) | 35,346) | 32,066) | 27,621) | 29,807) | 34,842) | 23,594) | 21,734) | 27,747) | 32,774) | 31,566) | 31,736) | 29,688) | 32,185) | 26,179) | 21,884) | 25,673) | 23,565) | 21,991) | 16,667) | 12,784) | 20,620) | 14,558) | 14,066) | 8,372) | ||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||||||
| Payables turnover1 | 5.72 | 5.62 | 5.32 | 5.70 | 6.38 | 5.74 | 4.65 | 6.58 | 7.09 | 5.41 | 4.62 | 4.65 | 4.44 | 4.57 | 4.03 | 4.77 | 5.29 | 4.19 | 4.18 | 3.99 | 4.90 | 6.06 | 3.43 | — | — | — | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Payables Turnover, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 4.28 | 4.44 | 4.15 | 4.67 | 4.25 | 4.02 | 4.21 | 4.55 | 4.43 | 3.97 | 3.80 | 4.37 | 4.00 | 4.20 | 4.07 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Cigna Group | 6.92 | 7.18 | 7.31 | 7.44 | 7.44 | 7.89 | 7.68 | 7.71 | 7.60 | 7.74 | 7.75 | 8.02 | 8.30 | 9.06 | 9.34 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | 21.32 | 22.08 | 18.07 | 18.75 | 19.22 | 19.38 | 19.14 | 18.49 | 20.72 | 20.50 | 19.72 | 18.61 | 21.70 | 21.06 | 20.13 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Danaher Corp. | 6.35 | 5.93 | 5.45 | 5.61 | 5.00 | 5.04 | 4.48 | 5.20 | 5.54 | 5.29 | 4.79 | 5.46 | 5.28 | 4.55 | 5.23 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | 7.54 | 7.57 | 7.47 | 7.48 | 7.35 | 7.28 | 7.59 | 7.31 | 7.30 | 7.31 | 7.75 | 8.32 | 8.42 | 8.48 | 9.25 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Humana Inc. | 7.84 | 7.78 | 8.17 | 8.07 | 7.61 | 7.63 | 8.35 | 7.76 | 7.81 | 7.32 | 7.57 | 7.20 | 7.12 | 7.90 | 8.97 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 11.10 | 12.99 | 13.78 | 12.01 | 12.68 | 14.36 | 14.45 | 14.13 | 13.71 | 14.80 | 18.35 | 12.46 | 13.18 | 10.69 | 11.08 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 4.60 | 4.62 | 4.46 | 5.14 | 5.41 | 5.67 | 4.98 | 5.56 | 5.19 | 5.56 | 4.72 | 4.96 | 4.84 | 4.89 | 4.69 | 5.31 | 5.16 | 4.98 | 5.56 | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | 7.08 | 6.86 | 7.26 | 7.07 | 6.90 | 6.78 | 7.63 | 6.98 | 6.97 | 6.58 | 7.29 | 7.40 | 8.02 | 6.96 | 7.21 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
1 Q2 2023 Calculation
Payables turnover
= (Cost of revenueQ2 2023
+ Cost of revenueQ1 2023
+ Cost of revenueQ4 2022
+ Cost of revenueQ3 2022)
÷ Accounts payable
= (48,880 + 52,626 + 51,457 + 47,627)
÷ 35,070 = 5.72
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Payables turnover | An activity ratio calculated as cost of goods sold divided by payables. | Abiomed Inc. payables turnover ratio increased from Q4 2022 to Q1 2023 and from Q1 2023 to Q2 2023. |
Working Capital Turnover
Abiomed Inc., working capital turnover calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||||||||
| Current assets | 1,062,798) | 1,060,359) | 976,473) | 885,006) | 871,487) | 729,873) | 787,965) | 693,691) | 716,621) | 619,689) | 635,863) | 636,576) | 647,432) | 677,365) | 677,197) | 628,728) | 561,599) | 497,297) | 494,271) | 422,198) | 370,170) | 350,915) | 326,958) | 333,419) | 319,870) | 300,288) | ||||||||
| Less: Current liabilities | 134,060) | 140,762) | 138,457) | 126,796) | 114,022) | 113,123) | 128,969) | 120,400) | 105,213) | 110,379) | 131,885) | 126,259) | 112,229) | 100,201) | 105,998) | 92,980) | 81,979) | 76,678) | 84,682) | 75,353) | 63,358) | 59,005) | 69,617) | 58,871) | 51,922) | 43,219) | ||||||||
| Working capital | 928,738) | 919,597) | 838,016) | 758,210) | 757,465) | 616,750) | 658,996) | 573,291) | 611,408) | 509,310) | 503,978) | 510,317) | 535,203) | 577,164) | 571,199) | 535,748) | 479,620) | 420,619) | 409,589) | 346,845) | 306,812) | 291,910) | 257,341) | 274,548) | 267,948) | 257,069) | ||||||||
| Revenue | 265,921) | 277,149) | 269,850) | 261,176) | 248,142) | 252,585) | 241,245) | 231,663) | 209,764) | 164,850) | 206,659) | 221,584) | 204,974) | 207,666) | 207,081) | 200,563) | 181,778) | 180,010) | 174,436) | 154,022) | 132,823) | 132,468) | 124,680) | 114,674) | 102,955) | 102,995) | ||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||||||
| Working capital turnover1 | 1.16 | 1.15 | 1.23 | 1.32 | 1.29 | 1.52 | 1.29 | 1.42 | 1.31 | 1.57 | 1.67 | 1.65 | 1.53 | 1.38 | 1.35 | 1.38 | 1.44 | 1.52 | 1.45 | 1.57 | 1.64 | 1.63 | 1.73 | — | — | — | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 4.39 | 4.21 | 4.48 | 3.92 | 3.63 | 4.13 | 3.87 | 3.98 | 4.02 | 3.99 | 4.06 | 4.52 | 5.02 | 6.84 | 6.64 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Cigna Group | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Danaher Corp. | 3.35 | 3.97 | 4.20 | 5.00 | 5.43 | 5.91 | 8.40 | 7.98 | 3.12 | 3.45 | 3.48 | 3.14 | 2.80 | 6.74 | 0.87 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | 7.69 | 7.60 | 8.37 | 9.11 | 8.85 | 8.65 | 7.23 | 6.79 | 6.67 | 5.38 | 6.39 | 5.98 | 5.40 | 6.81 | 6.11 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Humana Inc. | 9.34 | 8.98 | 10.27 | 10.54 | 9.53 | 9.27 | 8.67 | 7.47 | 7.38 | 7.61 | 7.42 | 6.04 | 6.14 | 6.91 | 7.19 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 1.03 | 1.15 | 1.29 | 1.21 | 1.17 | 1.26 | 1.22 | 1.17 | 1.03 | 0.88 | 0.77 | 0.80 | 0.88 | 1.23 | 1.23 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 2.82 | 3.84 | 2.97 | 2.21 | 2.13 | 2.15 | 2.15 | 2.02 | 2.00 | 2.44 | 2.48 | 2.03 | 2.13 | 2.16 | 2.26 | 2.54 | 2.30 | 2.24 | 2.32 | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
1 Q2 2023 Calculation
Working capital turnover
= (RevenueQ2 2023
+ RevenueQ1 2023
+ RevenueQ4 2022
+ RevenueQ3 2022)
÷ Working capital
= (265,921 + 277,149 + 269,850 + 261,176)
÷ 928,738 = 1.16
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Working capital turnover | An activity ratio calculated as revenue divided by working capital. | Abiomed Inc. working capital turnover ratio deteriorated from Q4 2022 to Q1 2023 but then slightly improved from Q1 2023 to Q2 2023. |
Average Inventory Processing Period
Abiomed Inc., average inventory processing period calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||||||||
| Inventory turnover | 1.96 | 2.05 | 2.00 | 2.03 | 2.05 | 2.05 | 2.00 | 1.88 | 1.85 | 1.68 | 1.68 | 1.61 | 1.56 | 1.55 | 1.60 | 1.74 | 1.82 | 1.93 | 1.96 | 1.87 | 2.01 | 2.10 | 2.02 | — | — | — | ||||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||||||||||
| Average inventory processing period1 | 186 | 178 | 182 | 180 | 178 | 178 | 183 | 194 | 197 | 217 | 217 | 227 | 234 | 236 | 228 | 210 | 201 | 189 | 186 | 195 | 181 | 174 | 181 | — | — | — | ||||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 139 | 132 | 118 | 108 | 113 | 109 | 102 | 105 | 111 | 122 | 122 | 135 | 142 | 125 | 119 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Cigna Group | 13 | 12 | 14 | 12 | 11 | 11 | 12 | 10 | 10 | 10 | 11 | 10 | 10 | 10 | 10 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | 22 | 24 | 26 | 25 | 25 | 27 | 27 | 27 | 27 | 29 | 31 | 29 | 28 | 29 | 30 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Danaher Corp. | 94 | 100 | 91 | 96 | 98 | 94 | 88 | 90 | 85 | 84 | 85 | 96 | 112 | 118 | 75 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 166 | 162 | 161 | 155 | 139 | 130 | 122 | 126 | 129 | 138 | 147 | 167 | 164 | 159 | 159 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 183 | 174 | 166 | 161 | 153 | 148 | 150 | 163 | 166 | 174 | 164 | 156 | 155 | 154 | 150 | 156 | 153 | 151 | 144 | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
1 Q2 2023 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 1.96 = 186
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Average inventory processing period | An activity ratio equal to the number of days in the period divided by inventory turnover over the period. | Abiomed Inc. number of days of inventory outstanding improved from Q4 2022 to Q1 2023 but then deteriorated significantly from Q1 2023 to Q2 2023. |
Average Receivable Collection Period
Abiomed Inc., average receivable collection period calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||||||||
| Receivables turnover | 11.37 | 11.59 | 11.39 | 11.28 | 10.87 | 10.55 | 8.72 | 8.74 | 9.92 | 9.72 | 9.93 | 8.33 | 8.70 | 9.25 | 8.47 | 8.35 | 9.30 | 9.50 | 8.48 | 8.39 | 8.80 | 8.86 | 8.24 | — | — | — | ||||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||||||||||
| Average receivable collection period1 | 32 | 31 | 32 | 32 | 34 | 35 | 42 | 42 | 37 | 38 | 37 | 44 | 42 | 39 | 43 | 44 | 39 | 38 | 43 | 44 | 41 | 41 | 44 | — | — | — | ||||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 56 | 53 | 52 | 52 | 58 | 59 | 55 | 55 | 55 | 60 | 68 | 64 | 60 | 60 | 62 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | 32 | 31 | 31 | 31 | 32 | 32 | 31 | 32 | 32 | 32 | 30 | 33 | 31 | 32 | 28 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Danaher Corp. | 50 | 51 | 57 | 51 | 54 | 53 | 57 | 55 | 56 | 58 | 66 | 63 | 65 | 69 | 65 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | 19 | 22 | 19 | 19 | 19 | 22 | 18 | 19 | 19 | 21 | 19 | 19 | 20 | 22 | 20 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Humana Inc. | 5 | 12 | 7 | 6 | 14 | 13 | 8 | 9 | 11 | 10 | 5 | 6 | 12 | 11 | 6 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 50 | 53 | 55 | 51 | 51 | 56 | 50 | 46 | 49 | 52 | 54 | 50 | 43 | 42 | 53 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 67 | 62 | 64 | 63 | 63 | 63 | 66 | 68 | 70 | 64 | 59 | 73 | 72 | 70 | 74 | 70 | 69 | 69 | 73 | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | 19 | 25 | 20 | 20 | 22 | 23 | 18 | 19 | 20 | 22 | 18 | 18 | 19 | 22 | 18 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
1 Q2 2023 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 11.37 = 32
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Average receivable collection period | An activity ratio equal to the number of days in the period divided by receivables turnover. |
Operating Cycle
Abiomed Inc., operating cycle calculation (quarterly data)
No. days
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||||||||
| Average inventory processing period | 186 | 178 | 182 | 180 | 178 | 178 | 183 | 194 | 197 | 217 | 217 | 227 | 234 | 236 | 228 | 210 | 201 | 189 | 186 | 195 | 181 | 174 | 181 | — | — | — | ||||||||
| Average receivable collection period | 32 | 31 | 32 | 32 | 34 | 35 | 42 | 42 | 37 | 38 | 37 | 44 | 42 | 39 | 43 | 44 | 39 | 38 | 43 | 44 | 41 | 41 | 44 | — | — | — | ||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||||||
| Operating cycle1 | 218 | 209 | 214 | 212 | 212 | 213 | 225 | 236 | 234 | 255 | 254 | 271 | 276 | 275 | 271 | 254 | 240 | 227 | 229 | 239 | 222 | 215 | 225 | — | — | — | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Operating Cycle, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 195 | 185 | 170 | 160 | 171 | 168 | 157 | 160 | 166 | 182 | 190 | 199 | 202 | 185 | 181 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | 54 | 55 | 57 | 56 | 57 | 59 | 58 | 59 | 59 | 61 | 61 | 62 | 59 | 61 | 58 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Danaher Corp. | 144 | 151 | 148 | 147 | 152 | 147 | 145 | 145 | 141 | 142 | 151 | 159 | 177 | 187 | 140 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 216 | 215 | 216 | 206 | 190 | 186 | 172 | 172 | 178 | 190 | 201 | 217 | 207 | 201 | 212 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 250 | 236 | 230 | 224 | 216 | 211 | 216 | 231 | 236 | 238 | 223 | 229 | 227 | 224 | 224 | 226 | 222 | 220 | 217 | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
1 Q2 2023 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 186 + 32 = 218
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Operating cycle | Equal to average inventory processing period plus average receivables collection period. | Abiomed Inc. operating cycle improved from Q4 2022 to Q1 2023 but then deteriorated significantly from Q1 2023 to Q2 2023. |
Average Payables Payment Period
Abiomed Inc., average payables payment period calculation (quarterly data)
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||||||||
| Payables turnover | 5.72 | 5.62 | 5.32 | 5.70 | 6.38 | 5.74 | 4.65 | 6.58 | 7.09 | 5.41 | 4.62 | 4.65 | 4.44 | 4.57 | 4.03 | 4.77 | 5.29 | 4.19 | 4.18 | 3.99 | 4.90 | 6.06 | 3.43 | — | — | — | ||||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||||||||||
| Average payables payment period1 | 64 | 65 | 69 | 64 | 57 | 64 | 79 | 55 | 51 | 67 | 79 | 78 | 82 | 80 | 91 | 77 | 69 | 87 | 87 | 91 | 74 | 60 | 107 | — | — | — | ||||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 85 | 82 | 88 | 78 | 86 | 91 | 87 | 80 | 82 | 92 | 96 | 83 | 91 | 87 | 90 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Cigna Group | 53 | 51 | 50 | 49 | 49 | 46 | 48 | 47 | 48 | 47 | 47 | 46 | 44 | 40 | 39 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | 17 | 17 | 20 | 19 | 19 | 19 | 19 | 20 | 18 | 18 | 19 | 20 | 17 | 17 | 18 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Danaher Corp. | 57 | 62 | 67 | 65 | 73 | 72 | 82 | 70 | 66 | 69 | 76 | 67 | 69 | 80 | 70 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | 48 | 48 | 49 | 49 | 50 | 50 | 48 | 50 | 50 | 50 | 47 | 44 | 43 | 43 | 39 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Humana Inc. | 47 | 47 | 45 | 45 | 48 | 48 | 44 | 47 | 47 | 50 | 48 | 51 | 51 | 46 | 41 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 33 | 28 | 26 | 30 | 29 | 25 | 25 | 26 | 27 | 25 | 20 | 29 | 28 | 34 | 33 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 79 | 79 | 82 | 71 | 67 | 64 | 73 | 66 | 70 | 66 | 77 | 74 | 75 | 75 | 78 | 69 | 71 | 73 | 66 | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | 52 | 53 | 50 | 52 | 53 | 54 | 48 | 52 | 52 | 56 | 50 | 49 | 46 | 52 | 51 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
1 Q2 2023 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 5.72 = 64
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Average payables payment period | An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. | Abiomed Inc. number of days of payables outstanding decreased from Q4 2022 to Q1 2023 and from Q1 2023 to Q2 2023. |
Cash Conversion Cycle
Abiomed Inc., cash conversion cycle calculation (quarterly data)
No. days
| Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||||||||
| Average inventory processing period | 186 | 178 | 182 | 180 | 178 | 178 | 183 | 194 | 197 | 217 | 217 | 227 | 234 | 236 | 228 | 210 | 201 | 189 | 186 | 195 | 181 | 174 | 181 | — | — | — | ||||||||
| Average receivable collection period | 32 | 31 | 32 | 32 | 34 | 35 | 42 | 42 | 37 | 38 | 37 | 44 | 42 | 39 | 43 | 44 | 39 | 38 | 43 | 44 | 41 | 41 | 44 | — | — | — | ||||||||
| Average payables payment period | 64 | 65 | 69 | 64 | 57 | 64 | 79 | 55 | 51 | 67 | 79 | 78 | 82 | 80 | 91 | 77 | 69 | 87 | 87 | 91 | 74 | 60 | 107 | — | — | — | ||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||||||
| Cash conversion cycle1 | 154 | 144 | 145 | 148 | 155 | 149 | 146 | 181 | 183 | 188 | 175 | 193 | 194 | 195 | 180 | 177 | 171 | 140 | 142 | 148 | 148 | 155 | 118 | — | — | — | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 110 | 103 | 82 | 82 | 85 | 77 | 70 | 80 | 84 | 90 | 94 | 116 | 111 | 98 | 91 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | 37 | 38 | 37 | 37 | 38 | 40 | 39 | 39 | 41 | 43 | 42 | 42 | 42 | 44 | 40 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Danaher Corp. | 87 | 89 | 81 | 82 | 79 | 75 | 63 | 75 | 75 | 73 | 75 | 92 | 108 | 107 | 70 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 183 | 187 | 190 | 176 | 161 | 161 | 147 | 146 | 151 | 165 | 181 | 188 | 179 | 167 | 179 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 171 | 157 | 148 | 153 | 149 | 147 | 143 | 165 | 166 | 172 | 146 | 155 | 152 | 149 | 146 | 157 | 151 | 147 | 151 | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-K (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-K (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-K (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-K (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-K (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-K (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30).
1 Q2 2023 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 186 + 32 – 64 = 154
2 Click competitor name to see calculations.
| Short-term activity ratio | Description | The company |
|---|---|---|
| Cash conversion cycle | A financial metric that measures the length of time required for a company to convert cash invested in its operations to cash received as a result of its operations; equal to average inventory processing period plus average receivables collection period minus average payables payment period. | Abiomed Inc. cash conversion cycle improved from Q4 2022 to Q1 2023 but then deteriorated significantly from Q1 2023 to Q2 2023. |